- Size
- 10mg
- Purity
- 99.79%
- Formula
- C129H215N33O55
Thymosin Alpha-1 is a 28-amino-acid, N-terminally acetylated peptide originally isolated from thymosin fraction 5, a thymic tissue extract characterised by Goldstein and colleagues. Its synthetic counterpart is designated thymalfasin. NMR work describes the free peptide as largely unstructured in water, adopting helical character in membrane-mimetic environments — a conformational flexibility the structural literature links to its interaction with cell-surface receptors.
Mechanistic reviews place its activity upstream in innate immune signalling rather than at a single target. Thymosin Alpha-1 is described as acting through Toll-like receptors on both myeloid and plasmacytoid dendritic cells, with downstream effects on dendritic-cell maturation, T-cell differentiation, and the balance of pro- and anti-inflammatory signalling. The reviews characterise it as a modulator that can shift immune signalling in either direction depending on baseline state, rather than a uniform stimulant.
Regulatory history, noted here as neutral background only: review articles record that the synthetic peptide is approved in more than 35 countries — marketed as Zadaxin in several of them — for hepatitis B and hepatitis C, and that it has been examined in trials across oncology, vaccine adjuvancy, and sepsis. That regulatory record attaches to licensed pharmaceutical product in those jurisdictions and says nothing about the research material supplied on this page.
Categorised as Longevity — Compounds for cellular-ageing and immune research.For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition.